Verdict: Curex is worth it if you have confirmed environmental allergies and cannot get to an allergist for shots. Skip it if one allergen is your whole problem.
Curex sells three things in one subscription: an IgE allergy blood test, telehealth consults, and custom-compounded sublingual immunotherapy drops. Testing runs $199 cash, and the $99 self-pay plan covers the drops as of August 21, 2026.
The drops are the part that needs scrutiny. They are compounded at a specialty pharmacy for each patient and used off-label in the US. Curex states plainly that the FDA does not review compounded products for safety or efficacy. That is the fact you need before you see a price.
Know Your DNA has no hands-on testing record for Curex, so this review works from current product pages, the posted legal documents, and professional-society guidance.
Key Takeaways
- Curex bundles testing, telehealth, and treatment. Self-pay drops run $99 per month as of August 21, 2026, or roughly $1,188 a year before testing.
- The drops are compounded and off-label. Curex discloses that the FDA does not review compounded products. The 2017 AAAAI/ACAAI/JCAAI focused practice parameter did not endorse off-label drops.
- The trial evidence does not match the product. Sublingual immunotherapy works for allergic rhinitis, but the studies used standardized tablets and European liquid extracts.
- Insurance covers testing and consults, not the drops. ACAAI states that allergy drops are not covered by most insurance, Medicare or Medicaid.
- A positive IgE result is sensitization, not a diagnosis. Skip the optional IgG food-sensitivity add-on, which AAAAI’s Choosing Wisely guidance advises against.
- Per BBB, Curex holds a C rating and is not accredited, with 42 complaints closed in the last 12 months as of August 21, 2026.
Our Verdict
We would buy Curex for a narrow reader. You have confirmed environmental allergic rhinitis, your symptoms line up with a known trigger, and you have run out of road with antihistamines and nasal steroids. Getting to an allergist every week or two for shots is not realistic for you.
Access is the strongest honest argument for this model. Immunotherapy you never start because the clinic is 90 minutes away helps nobody. You also need to absorb roughly $1,200 a year for three to five years.
Skip Curex if you have severe, unstable, or uncontrolled asthma. The same goes for any history of a severe systemic allergic reaction, or eosinophilic esophagitis. Those are contraindications on the FDA-approved sublingual tablet labels, which are the best available proxy for a compounded drop.
Skip it too if your allergy is limited to grass, ragweed, or dust mite. An FDA-approved tablet from an allergist is standardized, reviewed, and far more likely to be covered. A suspected food allergy with any history of a systemic reaction needs an in-person allergist, not a remote program.
What You Actually Get
Curex offers three testing routes: IgE ImmunoCAP blood testing at LabCorp or Quest sites, skin testing, and a lower-sensitivity at-home kit. Its own copy says blood testing beats scratch tests and finger-prick kits, an unusual admission about its own convenience option.
Turnaround runs 3 to 5 days in-lab, 6 to 10 days for the at-home kit, and 10 to 14 days for concierge phlebotomy. The panel is not a fixed allergen list. Curex states it is customized by your location and symptoms, and normally covers tree and weed pollens, dust mites, molds, cats, and dogs. It publishes no allergen count, so treat any specific number as unsourced.
Treatment covers cat and dog dander, dust mites, ragweed, grass, tree and cedar pollen, mold spores, and cockroach. Curex runs a separate food program and claims coverage of more than 90 food allergens. The usual at-home testing rule applies: the collection method matters less than what happens to the result afterward.
How the At-Home Test Works, and Where It Stops
An IgE test measures antibodies against a specific allergen. A positive result means you are sensitized to it. It does not mean you are allergic to it. AAAAI guidance holds that a direct correlation cannot be assumed between specific IgE antibodies and clinical disease.
Sensitization turns up routinely in people with no allergic disease at all, which is why a broad panel without a matching history is a bad idea. Cross-reactivity produces a classic mislabel. A birch-sensitized child shows low-level IgE to the peanut component Ara h 8, gets called peanut allergic, and keeps eating peanut without any reaction.
The same statistical logic behind false positives in consumer genetic testing applies here. Test enough things at once and some come back flagged for reasons unrelated to your symptoms.
Diagnosis needs history plus testing, read together against symptoms, timing, and exposure. Suspected food allergy sometimes needs an oral food challenge on top of that. Curex does route results to a clinician, a real advantage over a bare mail-order panel, but that interpretation still happens remotely.
One add-on we would decline outright is the optional IgG food-sensitivity panel. AAAAI’s Choosing Wisely guidance advises against unproven diagnostic tests including IgG testing. IgG titers have not been shown to predict benefit from cutting the target food, and the harms are over-diagnosis and unnecessary dietary restriction. Our 5Strands review applies the same warning to hair-sample bioresonance scanning.
How the Drops Work, and What the Evidence Says
Sublingual immunotherapy means holding small doses of your allergens under the tongue daily, so the immune system gradually stops overreacting. Curex describes the mechanism in terms of regulatory T cells and IgG4 blocking antibodies, matching the accepted account.
Curex describes a typical 3 to 5 year course and says benefit and durability vary by individual. It publishes no firm timeline to relief, so treat any “relief in X weeks” number you see elsewhere as marketing.
The regulatory status is the central fact of this review, and Curex discloses it directly. The drops are compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy. ACAAI calls allergy drops not FDA-approved and off-label in the United States.
The 2017 AAAAI/ACAAI/JCAAI focused practice parameter on sublingual immunotherapy did not endorse off-label drops. The reason is that no FDA-approved liquid product exists, and no standardized dosing sits behind the compounded ones.
The Cochrane review of sublingual immunotherapy for allergic rhinitis pooled 49 randomized trials, covering 2,333 people on treatment against 2,256 on placebo. Symptom scores improved with a standardized mean difference of -0.49, and medication use fell by -0.32.
Read that plainly: an effect around -0.3 to -0.5 is a small-to-moderate benefit. It is real and consistent across many trials, and nowhere near symptom elimination. That review dates to 2010, so pair it with newer work. A 2024 meta-analysis found both immunotherapy routes effective for respiratory allergy.
The gap you need to hold onto is what those trials actually tested. Nearly all of that evidence comes from single-allergen, fixed-dose, standardized products. The closest match to a drops product is a 2025 meta-analysis of index-of-reactivity liquid immunotherapy, and even that studies a standardized European preparation. Curex’s own dose and composition have not been through randomized trials, so tablet efficacy does not automatically transfer to a compounded drop.
Against allergy shots, comparative reviews find broadly similar symptom and medication outcomes. Shots produce more systemic reactions, and sublingual dosing produces more local mouth and throat reactions.
Against the FDA-approved tablets, the tradeoff is sharper. Oralair covers five grasses, Grastek covers Timothy grass, Ragwitek covers short ragweed, and Odactra covers house dust mite. Tablets are single-allergen, standardized, FDA-reviewed, and often covered by insurance. Curex drops are multi-allergen, compounded, not FDA-reviewed, and generally not covered as a drug.
Pricing, Subscription, and Cancellation
Self-pay runs $99 per month for environmental drops as of August 21, 2026, with all consultations included per Curex. That is about $1,188 a year before testing and the sign-up call. Testing is $199 cash or billed to insurance, and the food allergy plan is listed at $149 per month.
The insurance route is advertised from $39 per month. Curex states average patient responsibility of about $200 a year for consultations, a ceiling of $500 a year, and an annual treatment cost of $790 to $990. Curex also says drops are eligible for health savings account (HSA) and flexible spending account (FSA) funds.
Watch the insurance framing carefully. What gets billed is the testing and the consults. ACAAI says allergy drops are not covered by most insurance, Medicare or Medicaid, so the drops are realistically your cost. The sign-up call lists at $49 and showed $4.99 during a flash sale as of August 21, 2026.
Cancellation is where the reported friction lives. Curex says you can cancel at any time, but the Terms of Use narrow that. You can cancel or pause before your next order enters fulfillment. Once a product has entered fulfillment, you are responsible for the full cost, and compounding counts as fulfillment.
Fees are described as non-refundable, and prepaid annual plans get no prorated refund. Cancellation runs through phone or email rather than a button in the app. The Terms also carry mandatory binding arbitration in New York, and still show a November 1, 2021 effective date.
Per BBB, Curex is not accredited and holds a C rating. It shows 59 complaints closed in three years and 42 in the last 12 months as of August 21, 2026. Reported by users, the recurring themes are unexpected charges, refused refunds on prepaid plans, and continued billing after a cancellation request.
The complaints cluster on commercial terms rather than clinical harm, which lines up with the Terms. Run the same subscription math you would on any recurring health product, including at-home cholesterol tests.
Safety
The FDA-approved sublingual tablets require a supervised first dose from a physician experienced in allergic disease, with at least 30 minutes of observation. Curex’s model is fully remote, so that step does not happen. Whether it matters for a compounded drop at a lower starting dose is not settled, but the difference is real.
Those same tablets carry a boxed warning for severe allergic reactions, and patients must be prescribed auto-injectable epinephrine. Curex says it includes a prescription auto-injector. Make sure you have it in hand and know how to use it before your first dose.
Side effects are usually mild and local. Curex lists itchy mouth, throat, or ears, mild mouth or tongue swelling, and minor stomach upset. ACAAI independently describes sublingual side effects as local and mild, usually managed by adjusting the dose. Curex also states fewer than 0.1% systemic reactions in its own program, a first-party figure with no published methodology.
Contraindications on the approved tablet labels are the best proxy for drops. They cover severe, unstable, or uncontrolled asthma and a history of severe systemic allergic reaction. They also cover eosinophilic esophagitis and any severe local reaction after previous sublingual immunotherapy. If your asthma is not well controlled, sort that out with a physician first.
Privacy
Curex’s privacy policy lives at getcurex.com/legal/privacy-policy and was last updated September 6, 2024. It states that Curex has not sold personal information in the past twelve months and does not sell it. The first half is a backward-looking CCPA statement, not a permanent commitment.
Retention is open-ended. The policy says Curex keeps personal information for no longer than necessary for the purposes for which it is processed. Sharing covers service providers, affiliates, and healthcare providers, plus law enforcement and health authorities under specified circumstances. Third-party advertising technologies are used for targeted ads.
Deletion is framed as a California resident right, with denials permitted where retention is legally required, so we would not call it guaranteed or universal. The privacy concerns we track for consumer DNA companies apply to health-data companies too.
Alternatives
Wyndly is the closest competitor. It tests environmental allergens only, with drops at $99 per month billed annually or $110 billed quarterly, and a $249 self-pay test as of August 21, 2026. Its drops carry the same compounded, off-label status, and it has no food allergy program.
A board-certified allergist is the right call for severe or year-round symptoms with asthma, any history of anaphylaxis, an unclear trigger, or a child who needs treatment. An allergist can also prescribe an FDA-approved tablet, which gives you a standardized dose, supervised first dosing, and better odds of insurance coverage.
Testing-only options make sense if you want numbers without a treatment subscription. Consumer-initiated IgE panels through Quest or Labcorp OnDemand start well below Curex’s cash price, though you get results without interpretation. That tradeoff runs through our health-focused testing roundup: a cheap number only helps if someone qualified helps you act on it.
The Bottom Line
Curex is a reasonable buy for a specific reader. You have confirmed environmental allergic rhinitis, a real access barrier to in-office shots, and a budget for roughly $1,200 a year over three to five years. The testing is legitimate, and remote dosing solves the problem that keeps most people from ever starting immunotherapy.
What would flip our answer is a single-allergen picture. If grass, ragweed, or dust mite is your whole problem, an FDA-approved tablet through an allergist gives you standardization, regulatory review, and better coverage odds. Go in with eyes open on the commercial terms: pay monthly rather than prepaying a year, save the cancellation number on day one, and decline the IgG add-on.
